ANI Pharmaceuticals (ANIP) Rating Lowered to Hold at BidaskClub

BidaskClub cut shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a buy rating to a hold rating in a research report sent to investors on Thursday.

Several other analysts have also issued reports on ANIP. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 10th. ValuEngine lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday, July 28th. Cantor Fitzgerald set a $74.00 target price on shares of ANI Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, August 7th. Finally, Canaccord Genuity set a $75.00 target price on shares of ANI Pharmaceuticals and gave the company a buy rating in a research report on Thursday, August 16th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. ANI Pharmaceuticals presently has a consensus rating of Hold and an average target price of $72.67.

NASDAQ ANIP traded down $0.19 during trading hours on Thursday, hitting $51.91. 37,392 shares of the company’s stock traded hands, compared to its average volume of 100,628. The company has a current ratio of 3.84, a quick ratio of 2.89 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $598.45 million, a price-to-earnings ratio of 14.47 and a beta of 2.62. ANI Pharmaceuticals has a 52 week low of $48.51 and a 52 week high of $74.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.34 by ($0.21). The business had revenue of $47.27 million for the quarter, compared to the consensus estimate of $50.70 million. ANI Pharmaceuticals had a net margin of 0.06% and a return on equity of 27.76%. Sell-side analysts predict that ANI Pharmaceuticals will post 4.49 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sei Investments Co. boosted its position in shares of ANI Pharmaceuticals by 56.9% in the first quarter. Sei Investments Co. now owns 2,252 shares of the specialty pharmaceutical company’s stock worth $131,000 after purchasing an additional 817 shares during the period. Aperio Group LLC boosted its position in shares of ANI Pharmaceuticals by 21.3% in the second quarter. Aperio Group LLC now owns 5,799 shares of the specialty pharmaceutical company’s stock worth $387,000 after purchasing an additional 1,019 shares during the period. Globeflex Capital L P boosted its position in shares of ANI Pharmaceuticals by 10.8% in the second quarter. Globeflex Capital L P now owns 12,300 shares of the specialty pharmaceutical company’s stock worth $822,000 after purchasing an additional 1,200 shares during the period. Strs Ohio boosted its position in shares of ANI Pharmaceuticals by 10.7% in the third quarter. Strs Ohio now owns 13,500 shares of the specialty pharmaceutical company’s stock worth $763,000 after purchasing an additional 1,300 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of ANI Pharmaceuticals by 8.0% in the second quarter. Legal & General Group Plc now owns 17,876 shares of the specialty pharmaceutical company’s stock worth $1,198,000 after purchasing an additional 1,318 shares during the period. Institutional investors and hedge funds own 61.09% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

Featured Story: Market Capitalization – What it Means for Investors

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply